Host Tylah Tully looks at Optiscan (ASX:OIL) new US head and neck cancer study with Mayo Clinic.

The 35-patient study is part of Optiscan’s ongoing clinical collaboration with Mayo Clinic Rochester, with patient recruitment underway.

It will test the company’s InVue and InForm imaging platforms during and after head and neck tumour surgery.

Watch the full video here.